Lesson
Read the Polyene Membrane System
Amphotericin B is an amphipathic macrocyclic polyene that prefers fungal ergosterol but can also interact with mammalian cholesterol.
- Amphipathic structure
- Ergosterol
- Membrane channels
- Ion leakage
- Host cholesterol
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Locate the pharmacophore
The hydrophobic polyene face associates with sterols while the polar face and mycosamine group support membrane organization. This structure creates activity that formulation can redirect but not fundamentally replace.
Bind rather than synthesize
Amphotericin binds existing ergosterol and forms membrane permeability defects. It does not inhibit lanosterol 14 alpha demethylase and should not be confused with an azole.
Follow the ions
Transmembrane channels allow sodium, potassium, hydrogen, and chloride leakage. Membrane collapse supports fungal death while host exposure helps explain renal tubular electrolyte loss.
Preserve the therapeutic boundary
Systemic amphotericin belongs to serious, progressive fungal disease. Broad activity does not justify using a high-toxicity intravenous product for uncomplicated superficial infection.
Quick check
Lesson
Make Product Identity a Hard Stop
Deoxycholate, liposomal amphotericin, and lipid complex amphotericin share an active ingredient but differ in composition, PK, dose, toxicity, and preparation.
- Deoxycholate
- Liposomal
- Lipid complex
- Noninterchangeability
- Independent check
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Name the complete product
An order that says only amphotericin is incomplete. Product identity must survive prescribing, verification, preparation, barcode scanning, bedside handoff, and administration.
Protect the conventional ceiling
The deoxycholate label states that the total daily dose must not exceed 1.5 mg/kg. Orders near or above that limit require an immediate independent verification for a possible formulation error.
Do not infer dose equivalence
Liposomal amphotericin commonly uses higher numerical mg/kg doses than deoxycholate because its distribution and toxicity differ. Milligram-for-milligram substitution can be fatal.
Build an independent double check
A second clinician should verify product, weight, indication, calculation, vial count, concentration, diluent, route, line, filter when applicable, pump, and rate without relying on the first calculation.
Quick check
Lesson
Turn Broad Activity Into a Clinical Role
Amphotericin can cover severe yeast, mold, and endemic fungal disease, but activity must be joined to the organism, syndrome, site, host, source, and current guidance.
- Candida
- Cryptococcus
- Aspergillus
- Mucorales
- Endemic fungi
- Source control
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Use broad spectrum precisely
Many Candida, Cryptococcus, Aspergillus, Mucorales, Histoplasma, Blastomyces, and Coccidioides isolates can be susceptible. Species and susceptibility still matter.
Let severity justify toxicity
Progressive CNS, disseminated, pulmonary, bloodstream, endovascular, or deep-tissue disease can justify amphotericin exposure. Mucosal colonization and uncomplicated superficial infection generally do not.
Respect the compartment
An in vitro result does not guarantee CNS, eye, urine, bone, abscess, valve, or devitalized-tissue cure. Drug delivery, inflammation, companion therapy, and procedure needs remain visible.
Treat the source
Drainage, debridement, removal of infected hardware, relief of obstruction, and immune recovery can determine success. Escalating dose alone does not repair an uncontrolled source.
Quick check
Lesson
Protect the Dose Before It Reaches the Vein
Amphotericin products have formulation-specific reconstitution, dilution, line, filter, concentration, and infusion requirements.
- Sterile water
- Dextrose
- Saline incompatibility
- Line flush
- Controlled infusion
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Prepare liposomal amphotericin correctly
AmBisome is reconstituted with 12 mL of sterile water to 4 mg/mL, then diluted as directed. Saline, bacteriostatic solutions, and unapproved mixtures can cause precipitation.
Prepare deoxycholate separately
Conventional amphotericin is reconstituted with sterile water and diluted with 5 percent dextrose to the labeled infusion concentration. Its concentration and stability pathway are not the liposomal pathway.
Resolve the intravenous line
For liposomal amphotericin, flush an existing line with 5 percent dextrose before infusion or use a separate line. Confirm every carrier and co-infusion before connection.
Control the rate
AmBisome is generally infused over about 120 minutes and may be shortened only when tolerated under its label. Deoxycholate is given slowly over about 2 to 6 hours. Rapid intravenous administration is unsafe.
Quick check
Lesson
Classify the Infusion Physiology
Fever, chills, rigors, nausea, pain, blood pressure change, hypoxia, bronchospasm, and anaphylaxis can occur, but they do not share one mechanism or response.
- Fever and rigors
- Pain reaction
- Rate
- Premedication
- Anaphylaxis
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Assess before labeling
Record timing, airway, breathing, circulation, oxygenation, blood pressure, temperature, rash, wheeze, pain, and prior doses. A severe reaction receives emergency evaluation before it receives a convenient label.
Recognize the liposomal pattern
Flushing, back pain, chest tightness, or chest pain can appear within minutes of liposomal infusion and often resolves after stopping. Severe symptoms still require evaluation for anaphylaxis and cardiopulmonary disease.
Individualize premedication
A fixed cocktail is not required for every patient. Product, prior phenotype, severity, sedation risk, kidney risk, rate, and local protocol should determine acetaminophen, antihistamine, corticosteroid, meperidine, or other measures.
Treat anaphylaxis as an emergency
Immediately discontinue amphotericin during suspected anaphylaxis and begin emergency management. Do not treat airway compromise or shock as routine amphotericin chills.
Quick check
Lesson
Manage Kidney and Electrolytes as One System
Amphotericin can reduce renal perfusion, injure tubules, waste potassium and magnesium, and amplify the toxicity of surrounding drugs.
- Renal blood flow
- Tubular injury
- Potassium
- Magnesium
- Nephrotoxins
- Sodium strategy
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Use a mechanistic kidney model
Afferent vasoconstriction can reduce filtration while direct tubular injury impairs concentrating and electrolyte handling. Serum creatinine, urine output, hemodynamics, and electrolytes tell different parts of the story.
Join potassium to magnesium
Correct both deficits and consider ECG, digoxin, QT-active drugs, gastrointestinal loss, and ongoing renal wasting. Magnesium depletion can make hypokalemia difficult to correct.
Reduce the nephrotoxin field
Review aminoglycosides, calcineurin inhibitors, platinum agents, contrast, NSAIDs, diuretics, and hemodynamic stress. Necessary combinations require stronger surveillance and ownership.
Individualize sodium and volume
Hydration and sodium repletion can reduce deoxycholate nephrotoxicity in selected patients, but heart failure, edema, blood pressure, urine output, and sodium concentration determine tolerance.
Quick check
Lesson
Follow Flucytosine Into the Fungal Cell
Flucytosine uses fungal transport and activation to disrupt RNA and DNA synthesis, while oral absorption, CNS penetration, and renal elimination shape clinical exposure.
- Cytosine permease
- Cytosine deaminase
- RNA
- Thymidylate synthase
- CSF
- Renal clearance
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Enter selectively
Cytosine permease transports flucytosine into susceptible fungi. Reduced uptake or altered activation can produce resistance.
Activate inside the fungus
Fungal cytosine deaminase creates fluorouracil, which becomes metabolites that enter RNA or inhibit thymidylate synthase and DNA synthesis.
Use the PK advantage
Oral absorption is high, protein binding is low, and cerebrospinal fluid concentrations are clinically meaningful. These properties support CNS combination therapy but do not justify monotherapy.
Respect renal dependence
More than 90 percent of administered radioactivity is recovered in urine as intact drug. The usual half-life of about 2.4 to 4.8 hours can rise dramatically in anuria, so acute kidney injury can rapidly destabilize exposure.
Quick check
Lesson
Calculate Exposure, Then Measure Its Consequences
Flucytosine dosing is weight based and divided, while renal function, concentration timing, capsule strengths, CBC, liver tests, and symptoms determine safe continuation.
- mg per kg
- Every 6 hours
- 250 and 500 mg capsules
- Concentration
- CBC
- DPD deficiency
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Separate daily from per dose
The label describes 50 to 150 mg/kg/day divided every 6 hours. The 2024 cryptococcosis guideline commonly expresses 25 mg/kg per dose four times daily. State which unit is being used before calculating.
Make the capsule plan operational
Available 250 mg and 500 mg capsules require clinically appropriate rounding and a feasible capsule burden. Giving capsules a few at a time over 15 minutes can reduce nausea or vomiting.
Interpret concentration with context
Prolonged values above 100 mcg/mL are associated with greater gastrointestinal, hematologic, and hepatic toxicity. A result needs dose history, timing, renal trajectory, and an action plan.
Watch marrow, liver, and DPD risk
Frequent CBC and hepatic monitoring are essential. Complete DPD deficiency is contraindicated, and severe mucositis, diarrhea, neutropenia, or neurotoxicity should trigger urgent evaluation and consideration of stopping.
Quick check
Lesson
Use Synergy Without Losing the Toxicity Signal
Flucytosine resistance emerges rapidly alone, while amphotericin adds complementary activity and can also increase flucytosine exposure through renal injury.
- Synergy
- Resistance
- Cryptococcosis induction
- Fungal clearance
- Intracranial pressure
- Coupled toxicity
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Protect against monotherapy resistance
Loss of fungal uptake or activation can be selected during flucytosine monotherapy. A validated partner provides complementary killing and reduces the chance that one pathway determines failure.
Use current cryptococcosis induction
The 2024 global guideline identifies liposomal amphotericin 3 to 4 mg/kg daily plus flucytosine 25 mg/kg four times daily as the optimal induction option for CNS, disseminated, or severe pulmonary cryptococcosis in high-income settings.
Do not erase setting and host
The resource-limited HIV regimen using a single 10 mg/kg liposomal dose plus 14 days of flucytosine and fluconazole was not trialed in non-HIV CNS disease or other non-CNS syndromes. Evidence does not transfer automatically.
Monitor the coupled toxicity
Amphotericin-associated kidney injury can reduce flucytosine clearance. Creatinine, concentration, CBC, liver tests, gastrointestinal symptoms, neurologic status, potassium, and magnesium belong in one loop.
Quick check
Lesson
Close the High-Risk Antifungal Loop
Safe therapy joins diagnosis, exact product, calculation, preparation, administration, toxicity surveillance, microbiologic response, transition, and result ownership.
- Baseline
- Daily trajectory
- Failure audit
- Transition
- Pregnancy and lactation
- Education boundary
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Keep product, exposure, physiology, microbiology, and ownership connected at every step.
Verify the baseline
Confirm syndrome, organism evidence, site, source, exact formulation, dosing weight, renal function, potassium, magnesium, CBC, liver tests, medication list, pregnancy and lactation context, and monitoring owner.
Recalculate after change
A rising creatinine can increase amphotericin risk and flucytosine exposure at the same time. Reassess formulation, dose, interval, concentration, nephrotoxins, electrolytes, volume, and dialysis without delay.
Audit failure broadly
Reopen diagnosis, organism, susceptibility, site, source, dose, product, line, adherence, concentration, immune recovery, cultures, imaging, and inflammatory timing before blind escalation.
Own the transition
Document induction end criteria, consolidation or maintenance, culture and clinical response, toxicity recovery, interactions, oral access, adherence, laboratory follow-up, symptom escalation, and responsible clinician.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 176 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.